Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Assets (2019 - 2025)

Revolution Medicines has reported Assets over the past 7 years, most recently at $2.4 billion for Q4 2025.

  • Quarterly results put Assets at $2.4 billion for Q4 2025, down 7.97% from a year ago — trailing twelve months through Dec 2025 was $2.4 billion (down 7.97% YoY), and the annual figure for FY2025 was $2.4 billion, down 7.97%.
  • Assets for Q4 2025 was $2.4 billion at Revolution Medicines, up from $2.3 billion in the prior quarter.
  • Over the last five years, Assets for RVMD hit a ceiling of $2.6 billion in Q4 2024 and a floor of $632.8 million in Q2 2022.
  • Median Assets over the past 5 years was $1.1 billion (2023), compared with a mean of $1.4 billion.
  • Biggest five-year swings in Assets: decreased 18.25% in 2022 and later surged 153.93% in 2023.
  • Revolution Medicines' Assets stood at $738.0 million in 2021, then grew by 10.02% to $811.9 million in 2022, then surged by 153.93% to $2.1 billion in 2023, then grew by 24.09% to $2.6 billion in 2024, then fell by 7.97% to $2.4 billion in 2025.
  • The last three reported values for Assets were $2.4 billion (Q4 2025), $2.3 billion (Q3 2025), and $2.4 billion (Q2 2025) per Business Quant data.